In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response

Henry S Sacks

doi:10.7326/J24-0022

In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response

Ann Intern Med. 2024 May;177(5):JC51. doi: 10.7326/J24-0022. Epub 2024 May 7.

Author

Henry S Sacks¹

Affiliation

¹ Icahn School of Medicine at Mount Sinai, New York, NY, USA (H.S.S.).

PMID: 38710079
DOI: 10.7326/J24-0022

Abstract

Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12:294-304. 38184008.

Publication types

Randomized Controlled Trial

MeSH terms

Administration, Oral
Anti-Bacterial Agents* / administration & dosage
Anti-Bacterial Agents* / therapeutic use
Clarithromycin* / administration & dosage
Clarithromycin* / therapeutic use
Community-Acquired Infections* / drug therapy
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Pneumonia / drug therapy
Pneumonia, Bacterial / drug therapy